Research
Hormonal
Incretin-based therapies have transformed the management of obesity and type 2 diabetes, with GLP-1RAs achieving levels of weight loss that begin to narrow the gap with metabolic surgery in selected populations.
Practitioners should consider incretin-based therapies as effective options for weight management in patients with obesity and type 2 diabetes.
StrongSupportsmedium confidence
Incretin-based therapies have transformed the management of obesity and type 2 diabetes, with GLP-1RAs achieving levels of weight loss that begin to narrow the gap with metabolic surgery in selected populations.
Why this rating
The claim is based on recent human trial data.
Source
Beyond <scp>GLP</scp> ‐1 Monotherapy: Novel Multi‐Agonists, Amylin Analogues, and Combination Strategies in Obesity and Type 2 Diabetes
Mikhail Khachaturov et al. · Diabetes Obesity and Metabolism · 2026
review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →